Investors

Innate Pharma S.A is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

12-Jul-21

NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF JULY 1, 2021

Marseille, France, July 12, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (the “ Company ” - Euronext

6-Jul-21

Update on Avdoralimab Phase 2 FORCE Trial in COVID-19 Patients with Severe Pneumonia

Marseille, France, July 06, 2021 (GLOBE NEWSWIRE) -- Investigator-sponsored FORCE trial did not meet primary endpoints Company will stop exploring avdoralimab in COVID-19 Investigator-sponsored avdoralimab clinical trial in inflammation will continue Innate Pharma SA (Euronext Paris: IPH – ISIN:

22-Jun-21

Innate Pharma presents preliminary data from TELLOMAK trial showing clinical response for lacutamab in mycosis fungoides

Marseille, June 22, 2021 (GLOBE NEWSWIRE) -- First data set from TELLOMAK establish es safety, clinical response s and skin improvement in patients with mycosis fungoides that express KIR3DL2 Data support continued development of lacutamab for KIR3DL2-expressing T -c ell l ymphomas Results